MannKind Corporation (NASDAQ: MNKD)
MannKind stock has been having an incredibly rough time lately. While the downtrends do make sense, I don’t think that they will continue for very much longer. We’ll get into that later. For now, there’s big news surrounding MNKD! Tomorrow, the company will be giving a presentation. Although, they have been relatively silent with regard to what the presentation will be about, I have a couple of ideas. Today, I’ll share what I believe is coming from the MNKD presentation, explain why the stock has been having a rough time, and explain why I still believe the stock is headed in the upward direction in the long run. So, let’s get right to it…
What I’m Expecting To See From The MannKind Presentation Tomorrow
As mentioned above, MannKind will be providing a big presentation tomorrow. The presentation will be hosted at the Aegis Capital Corp. 2015 Growth Conference at 9:30 am Pacific time. While the company hasn’t been very clear about what it is presenting, I have a few ideas of what we can expect to see…
There are three things that MNKD investors want to hear about Afrezza and I’m expecting to see details in the presentation tomorrow:
- Insurance Coverage – First and foremost, insurance coverage plays a key role in sales of any medication. While Afrezza hasn’t been covered by insurance companies yet, there has been quite a bit of discussion revolving around insurance. In fact, recently it has been predicted that about 80% of major insurance companies will be covering Afrezza in one way or another relatively soon. Now, investors will be looking to the presentation to hear more details on that front.
- Regulatory Approval – Another big topic of conversation surrounding MannKind has been regulatory approval in Europe and Asia. During the last earnings call, interest was sparked, but we haven’t heard anything about approval in these areas since. So, I’d imagine that this would be on the docket as well.
- Sales – Finally, sales of Afrezza have been the number one issue for MNKD. Investors want to know how sales are going to be picked up. This may also be discussed in the presentation.
When investors think about MNKD, the first thing that comes to mind is Afrezza. However, for me, the company represents far more than that. In fact, they have mentioned that they plan on furthering the development of other treatments using their proprietary technology. No one knows exactly what these treatments are. Nonetheless, I have a feeling that we will be hearing more on that front during tomorrow’s presentation as well.
Why I Still Believe In MNKD
While the overall sentiment on MNKD has moved more to the bearish side of the fence, I still have a relatively bullish opinion on the stock. The reality is that, although Afrezza has had a rough start, I’m expecting sales to pick up in the long run. As more advertising becomes available and insurance coverage starts, I think we’re going to see a big change in direction with regard to sales. On the other hand, it’s also important that MNKD is working to use technosphere in other indications. What indications these might be… who knows at this point? One thing we do know is that they are working on it! Hopefully we’ll hear more about that in tomorrow’s presentation. To sum it up, I’m still a bull!
What Do You Think?
Where do you think MNKD is headed and why? Let us know in the comments below!
[Image Courtesy of News Times]